ECKERT+ZIEGLERINH O.N. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ECKERT+ZIEGLERINH O.N. - More news...
ECKERT+ZIEGLERINH O.N. - More news...
- EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
- EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
- EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
- EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
- EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
- EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
- EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
- EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
- EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
- EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
- EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
- EQS-News: Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
- EQS-News: Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
- EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
- EQS-News: Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
- EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
- EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
- EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
- EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
- EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
- EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
- EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
- EQS-News: Eckert & Ziegler Receives Award for Professional Training
- EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
- EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
- EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
- EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
- EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
- EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
- EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
